Engineered T Cells Market

Global Engineered T Cells Market: Introduction

• Engineered T cells are the T cells made out of research carried out in the areas of molecular biology and tissue engineering
• These are specifically modified T cells used primarily in the treatment of several autoimmune disorders occurring in the therapeutic areas of skin diseases, orthopedic problems, cardiovascular & neurodegenerative diseases, immune deficient disorders, and cancer
• Delivery of engineered T cells in the body stimulates the immune system and changes antigen escape. Engineered T cells are inserted in the body to target cancer cells for effective treatment and to overcome immunosuppressive tumor environments.

Key Drivers and Restraint of Global Engineered T Cells Market

• According to the WHO, cancer is the second leading cause of death in the world. In 2018, global cancer burden was estimated to have risen to 18.1 million new cases and 9.6 million deaths. Rise in prevalence of cancer and other autoimmune diseases is projected to boost the global engineered T cells market.
• According to the World Health Organization (WHO), population aged 60 years and above is anticipated to rise from 900 million in 2015 to 2 billion in 2050. Increase in geriatric population leads to surge in incidence of age-related illnesses such as cancer and orthopedic disorders. This is expected to boost the growth of the global engineered T cells market.
• Increase in research & development in biopharmaceutical & biotechnology companies is likely to propel the global engineered T cells market during the forecast period
• Technological advancements in the health care industry with respect to cellular immunotherapy and rise in awareness among the population about new treatments available using engineered T cells are projected to propel the global market
• However, high investment required in research & development and stringent rules & regulations by governing authorities for approval are anticipated to restrain the global engineered T cells market

North America to Lead Global Engineered T Cells Market

• In terms of region, the global engineered T cells market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
• North America accounted for major share of the global engineered T cells market in 2020, owing to presence of large number of leading companies and expansion of research & development activities in the U.S. Moreover, increased medical reimbursement and advanced health care drive the market in the region. Furthermore, high demand for lung cancer treatment drives the market in North America.
• Europe was the second largest market for engineered T cells in 2020 due to increase in number of cancer cases and presence of well-established health care infrastructure
• The engineered T cells market in Asia Pacific is projected to grow at a rapid pace during the forecast period owing to large patient pool, low cost of clinical trials, and availability of skilled work force
• The engineered T cells market in Latin America and Middle East & Africa is likely to expand at a sluggish pace during the forecast period, due to the lack of presence of major players, developing economies, and below par health care infrastructure in the region

Key Players Operating in Global Engineered T Cells Market

• Autolus Limited
• Kuur Therapeutics (Athenex, Inc.)
• Gilead Sciences, Inc.
• Novartis AG
• Pfizer, Inc.
• Precision Biosciences
• Bellicum Phamaceuticals, Inc.
• Cogent Biosciences, Inc.
• Juno Therapeutics, Inc.
• Celgene Corporation
• bluebird bio, Inc.
• Sorrento Therapeutics, Inc.
• Miltenyi Biotec
• Celyad
• Cartesian Therapeutics, Inc.
• Amgen, Inc.
• Other players

Global Engineered T Cells Market: Research Scope

Global Engineered T Cells Market, by Type

• Engineered T Cell Receptor (TCR) Therapy
• Chimeric Antigen Receptor (CAR) T Cell Therapy

Global Engineered T Cells Market, by Application

• Lymphomas
• Leukemias
• Multiple Myeloma
• Lung Cancer
• Breast Cancer
• Colorectal cancer
• Others

Global Engineered T Cells Market, by End-user

• Hospitals
• Cancer Research & Treatment Centers
• Research Laboratories
• Specialty Clinics
• Others

Global Engineered T Cells Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa